WO2011060123A1 - Nutritional composition for promoting gut microbiota balance and health - Google Patents

Nutritional composition for promoting gut microbiota balance and health Download PDF

Info

Publication number
WO2011060123A1
WO2011060123A1 PCT/US2010/056321 US2010056321W WO2011060123A1 WO 2011060123 A1 WO2011060123 A1 WO 2011060123A1 US 2010056321 W US2010056321 W US 2010056321W WO 2011060123 A1 WO2011060123 A1 WO 2011060123A1
Authority
WO
WIPO (PCT)
Prior art keywords
colon
nutritional composition
decreased
fos
health
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/056321
Other languages
English (en)
French (fr)
Inventor
Zamzam Roughead (Fariba)
Jalil Benyacoub
Claudia Roessle
Jennifer Rae Mager
Julie Ann Swanson
Norman Alan Greenberg
Douglas Richard Bolster
Clara Lucia Garcia Rodenas
Florence Rochat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011060123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PH1/2012/500687A priority Critical patent/PH12012500687A1/en
Priority to EP10779417.4A priority patent/EP2498626B1/en
Priority to CN2010800498229A priority patent/CN102595934A/zh
Application filed by Nestec SA filed Critical Nestec SA
Priority to ES10779417.4T priority patent/ES2545597T3/es
Priority to RU2012123959/13A priority patent/RU2012123959A/ru
Priority to BR112012011294-5A priority patent/BR112012011294B1/pt
Priority to HK12113418.3A priority patent/HK1172516B/en
Priority to US13/502,918 priority patent/US9192179B2/en
Priority to MX2012004778A priority patent/MX336032B/es
Priority to IN3632DEN2012 priority patent/IN2012DN03632A/en
Priority to CA2777941A priority patent/CA2777941C/en
Priority to DK10779417.4T priority patent/DK2498626T3/en
Priority to AU2010319490A priority patent/AU2010319490B2/en
Priority to JP2012538966A priority patent/JP6006117B2/ja
Publication of WO2011060123A1 publication Critical patent/WO2011060123A1/en
Anticipated expiration legal-status Critical
Priority to US14/887,497 priority patent/US10015978B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • FIGS. 5A-5E show data for the effects of Blend 1 (designated as “SHIME 1”) and Blend 1+ (designated as “SHIME 2”) on the production in the different colon vessels of the SHIME experiements.
  • the data is presented per experiment week. Differences in ACFA concentrations among the colon compartments were evaluated by means of a one-way ANOVA, and individual means were compared using the Tukey's Test.
  • the nutritional composition further comprises protein.
  • the nutritional composition is used in a method of increasing absorption of vitamins and nutrients in an individual's intestine and colon.
  • the method includes administering to an individual who desires such increased adsorption an effective amount of the nutritional composition in order to specifically increase absorption of vitamins or calcium and other minerals or vitamins and minerals in the individual.
  • the vitamins are vitamin D, folates, B12, etc.
  • the minerals are at least magnesium or calcium.
  • the method assists in muscle growth.
  • the method prevents muscle mass depletion.
  • the method improves muscle mass recovery after illness or injury.
  • the nutritional composition is used in a method of use of an effective amount of the nutritional composition for long-term administration.
  • the nutritional composition is used in a method for improving bacterial balance in a pediatric patient by administering to an individual who can benefit from the same an effective amount of the nutritional composition wherein there is decreased TH1/TH2 imbalance, TH1/TH2 imbalance is a favoring of the TH2 subset.
  • the decreased TH1/TH2 imbalance leads to a decreased incidence of allergies.
  • the decreased TH1/TH2 imbalance leads to a decreased incidence of atopic dermatitis.
  • the decreased TH1/TH2 imbalance leads to a decreased incidence of asthma.
  • the decreased TH1/TH2 imbalance leads to a decreased incidence of food allergies.
  • This project was aimed at renovating a supplement with an innovative nutritional concept to increase the product's value proposition in the benefit area of growth and protection (reinforces child defenses).
  • pro-and prebiotic supplemented formula does not change the tolerance of enteral nutrition in the PICU. Moreover, such formula is safe and promotes a positive balance of the microbiota composition in critically ill children.
  • Blend 1 showed bifidogenic properties.
  • the increase in Bifidobacteria induced by Blend 1 is statistically higher than Blend 1+ , yet partial replacement by acacia gum still increased Bifidobacteria, confirming that this replacement has no negative consequences for its prebiotic activity.
  • Blend 1+ induced a higher increase in Lactobacilli in the ascending colon as compared to Blend 1 .
  • Blend 1+ acidified more gradually and throughout the complete simulated colon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
PCT/US2010/056321 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health Ceased WO2011060123A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2012538966A JP6006117B2 (ja) 2009-11-12 2010-11-11 腸内微生物叢バランス及び健康を促進するための栄養組成物
US13/502,918 US9192179B2 (en) 2009-11-12 2010-11-11 Methods for promoting gut microbiota balance
CN2010800498229A CN102595934A (zh) 2009-11-12 2010-11-11 用于促进肠微生物群平衡和健康的营养组合物
IN3632DEN2012 IN2012DN03632A (enExample) 2009-11-12 2010-11-11
ES10779417.4T ES2545597T3 (es) 2009-11-12 2010-11-11 Composición nutritiva para fomentar el equilibrio de la flora intestinal y para fomentar la salud
RU2012123959/13A RU2012123959A (ru) 2009-11-12 2010-11-11 Питательная композиция, способствующая балансу микробиоты и оказывающая благоприятное воздействие на состояние здоровья
BR112012011294-5A BR112012011294B1 (pt) 2009-11-12 2010-11-11 Composição nutricional para administração a um indivíduo
HK12113418.3A HK1172516B (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health
MX2012004778A MX336032B (es) 2009-11-12 2010-11-11 Composicion nutricional para promover el balance y salud de la microbiota intestinal.
PH1/2012/500687A PH12012500687A1 (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health
EP10779417.4A EP2498626B1 (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health
CA2777941A CA2777941C (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health
DK10779417.4T DK2498626T3 (en) 2009-11-12 2010-11-11 FOOD COMPOSITION TO PROMOTE GAS MICROFLORAL BALANCE AND HEALTH
AU2010319490A AU2010319490B2 (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health
US14/887,497 US10015978B2 (en) 2009-11-12 2015-10-20 Nutritional composition for promoting gut microbiota balance and health

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26049509P 2009-11-12 2009-11-12
US61/260,495 2009-11-12
US26443009P 2009-11-25 2009-11-25
US61/264,430 2009-11-25
US39480510P 2010-10-20 2010-10-20
US61/394,805 2010-10-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/502,918 A-371-Of-International US9192179B2 (en) 2009-11-12 2010-11-11 Methods for promoting gut microbiota balance
US14/887,497 Division US10015978B2 (en) 2009-11-12 2015-10-20 Nutritional composition for promoting gut microbiota balance and health

Publications (1)

Publication Number Publication Date
WO2011060123A1 true WO2011060123A1 (en) 2011-05-19

Family

ID=43567734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/056321 Ceased WO2011060123A1 (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health

Country Status (14)

Country Link
US (2) US9192179B2 (enExample)
EP (1) EP2498626B1 (enExample)
JP (2) JP6006117B2 (enExample)
CN (2) CN104206946A (enExample)
AU (1) AU2010319490B2 (enExample)
BR (1) BR112012011294B1 (enExample)
CA (1) CA2777941C (enExample)
DK (1) DK2498626T3 (enExample)
ES (1) ES2545597T3 (enExample)
IN (1) IN2012DN03632A (enExample)
MX (1) MX336032B (enExample)
PH (1) PH12012500687A1 (enExample)
RU (1) RU2012123959A (enExample)
WO (1) WO2011060123A1 (enExample)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175639A1 (en) * 2011-06-22 2012-12-27 Universite De Rouen Arabinogalactan proteins for use as an antiparasitic agent
WO2013054001A1 (en) * 2011-10-12 2013-04-18 Gut Guide Oy Raising and diagnosing of serotonin level
WO2013067147A1 (en) * 2011-11-01 2013-05-10 Jimmy Lu A composition and method of delivery of l-arabinose and select compounds
ITRM20120084A1 (it) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola Miscela prebiotica.
WO2014007636A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
KR20150088263A (ko) * 2012-11-27 2015-07-31 상하이 지아오통 유니버시티 장 미생물무리 균형을 위한 조성물 및 이의 제조 및 용도
EP2768312B1 (en) 2011-10-18 2015-12-09 Nestec S.A. Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
JP2015535280A (ja) * 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン 胃腸管において有益な細菌を刺激する方法及び組成物
WO2016019597A1 (zh) * 2014-08-07 2016-02-11 逯明福 综合营养粉及其制备方法
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
JP2016509002A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
JP2016516743A (ja) * 2013-03-28 2016-06-09 クラサド インコーポレイテッド 精神神経疾患または老化における認知機能障害および情緒障害の予防または治療に使用するためのガラクトオリゴ糖組成物
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN108245530A (zh) * 2016-12-28 2018-07-06 兰州奇正生态健康品有限公司 一种具有润肠通便作用的组合物及其制备方法与用途
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
EP3466276A1 (en) 2017-10-05 2019-04-10 Pharmactive Biotech Products, S.L. Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2020127630A1 (en) * 2018-12-19 2020-06-25 Cosucra Groupe Warcoing S.A. Composition comprising chicory root and pea cell wall fiber for treating brachyspira infections
WO2020161522A1 (en) * 2019-02-06 2020-08-13 Thd S.P.A. Fiber-based composition
WO2020178391A1 (fr) * 2019-03-05 2020-09-10 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
WO2020150389A3 (en) * 2019-01-18 2020-11-05 Cp Kelco U.S., Inc. Prebiotic composition and its use
WO2020239996A1 (en) 2019-05-29 2020-12-03 N.V. Nutricia Non-digestible oligosaccharides for decreased colonic protein fermentation
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US11109603B2 (en) 2011-06-20 2021-09-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
WO2022122958A1 (en) 2020-12-09 2022-06-16 N.V. Nutricia Fibre mixture for young children
EP4119135A1 (fr) * 2021-07-13 2023-01-18 Luxia Scientific Methodes pour reequilibrer la flore intestinale chez les patients souffrant de la maladie de parkinson
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
EP3866615B1 (en) 2018-10-15 2023-08-30 Freedom Health, LLC Dietary supplement for treating dysbiosis
WO2023209258A1 (es) * 2022-04-26 2023-11-02 Servicio Andaluz De Salud Composición para la rehabilitación intestinal
US12083151B2 (en) 2012-11-23 2024-09-10 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
RU2828960C1 (ru) * 2024-05-16 2024-10-21 Общество С Ограниченной Ответственностью "Нутризет" Способ лечения питательной недостаточности у больных с сепсисом энтеральной смесью, содержащей метабиотический комплекс и β-глюканы
US12214002B2 (en) 2017-10-30 2025-02-04 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
GR1011003B (el) * 2024-02-28 2025-07-22 Cloudpharm Private Company, Συμπληρωμα διατροφης για την αντιμετωπιση της απωλειας της οστικης πυκνοτητας (οστεοπενια)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012011294B1 (pt) * 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
NZ612455A (en) * 2010-12-31 2015-02-27 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
CN105555286A (zh) * 2013-03-15 2016-05-04 微生物治疗有限责任公司 活化的大豆豆荚纤维
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
WO2014165975A1 (en) * 2013-04-11 2014-10-16 Bright Drinks Inc. Compositions for prevention and/or treatment of gastrointestinal imbalances in digestive disorders
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
US9943559B2 (en) * 2013-12-20 2018-04-17 Nestec S.A. Nutritional compositions for reducing intestinal pathogens
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
US9539344B2 (en) 2014-09-30 2017-01-10 Kimberly-Clark Worldwide, Inc. Creped prebiotic tissue
US10441603B2 (en) 2014-09-30 2019-10-15 Kimberly-Clark Worldwide, Inc. Synergistic prebiotic composition
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
CN104432069A (zh) * 2014-12-22 2015-03-25 威海百合生物技术股份有限公司 一种肠胃通畅片
JP6338113B2 (ja) * 2015-03-31 2018-06-06 株式会社東洋新薬 除脂肪体重の増加剤
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
AU2016383512A1 (en) * 2015-12-31 2018-05-17 Société des Produits Nestlé S.A. Composition for improving mouthfeel
EP4257194A3 (en) * 2016-02-04 2023-12-20 Universiteit Gent Use of microbial communities for human and animal health
AU2017252409B2 (en) 2016-04-20 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
CA3038061A1 (en) * 2016-09-22 2018-03-29 The University Of Chicago Immune response modulation using live biotherapeutics, for conditions such as allergy desensitization
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
EP3554518A4 (en) 2016-12-15 2020-07-29 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR MODULATING THE GROWTH OF A GENETICALLY MODIFIED INTESTINAL BACTERIAL CELL
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
ES2683014B1 (es) * 2017-03-23 2019-01-16 Cuetara S L Galleta infantil sin azúcares añadidos
RU2740156C1 (ru) 2017-06-21 2021-01-12 Эбботт Лабораториз Способы улучшения роста полезных бактерий в желудочно-кишечном тракте
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
GB2566971B (en) * 2017-09-28 2020-12-02 Mjn Us Holdings Llc Infant formula having decreased protein content
IT201700108033A1 (it) 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
IT201700108039A1 (it) * 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
US20200261516A1 (en) * 2017-10-31 2020-08-20 Morinaga Milk Industry Co., Ltd. Composition for Increasing Muscle Mass
US11484547B2 (en) * 2018-01-08 2022-11-01 Performance Labs PTE. LTD. Compositions and methods for cholesterol, glucose and microbiome control
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
WO2020185857A1 (en) * 2019-03-12 2020-09-17 The Board Of Regents Of The University Of Texas System Simultaneous blood glucose monitoring and gastric emptying scintigraphy
CN109820865A (zh) * 2019-04-09 2019-05-31 福州大学 低聚木糖和部分水解的瓜尔豆胶复配组合物在预防肥胖及保健品中的应用
JP7321503B2 (ja) * 2019-05-21 2023-08-07 フジ日本精糖株式会社 イヌリンを含む筋肉量減少抑制又は骨密度減少抑制剤
CN114366826A (zh) * 2019-07-09 2022-04-19 大连大学 一种落叶松阿拉伯半乳聚糖组合物的制备方法及其灭菌处理装置
RS66685B1 (sr) * 2019-08-30 2025-05-30 Hem Pharma Inc Postupak za proveru personalizovane supstance koja poboljšava crevnu sredinu pomoću pmas postupka
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN110679955A (zh) * 2019-11-11 2020-01-14 成都高新区九州华昀医疗美容门诊部有限公司 可改善肠道功能的大鲵活性肽营养组合物
JP2023515187A (ja) * 2020-02-27 2023-04-12 アボット・ラボラトリーズ 骨の健康を改善する方法
EP4138873A1 (en) * 2020-04-24 2023-03-01 Société des Produits Nestlé S.A. Composition comprising fibre and mulberry
CN111440841A (zh) * 2020-05-19 2020-07-24 爱礼康生物医药（苏州）有限公司 一种检测膳食纤维对人肠道菌活性影响的方法
EP4152961A1 (en) * 2020-05-20 2023-03-29 Société des Produits Nestlé S.A. Beneficial effect of poaceae and/or leguminoseae fiber on survivability and metabolic activity of bifidobacterium longum
AU2021281622A1 (en) * 2020-05-29 2022-12-01 Societe Des Produits Nestle Sa Compositions and methods for digestive health in an animal
JP7688866B2 (ja) * 2020-07-14 2025-06-05 物産フードサイエンス株式会社 筋肉量率を増加させる剤および方法、ならびに体脂肪率を減少させる剤および方法
WO2022083858A1 (en) * 2020-10-21 2022-04-28 Compagnie Gervais Danone Acacia gum for iron induced microbial dysbiosis
JP2022072243A (ja) * 2020-10-29 2022-05-17 帝人株式会社 腸内細菌叢改善用組成物及び腸内腐敗物質産生抑制用組成物
CN112715669A (zh) * 2020-11-24 2021-04-30 本溪木兰花乳业有限责任公司 一种改善便秘的牛奶制品及其制备方法
US20240366654A1 (en) * 2021-07-16 2024-11-07 Purdue Research Foundation Prebiotic composition and method of use to improve gastrointestinal health in patients with dysbiosis and leaky gut
CN113826892A (zh) * 2021-09-17 2021-12-24 潍坊易北特健康食品有限公司 一种基于肠道微生物调控特定胆汁酸的组合物及制备方法
JP7766703B2 (ja) * 2021-09-29 2025-11-10 森永乳業株式会社 トレオン酸含有組成物及びその製造方法
JP2023055389A (ja) * 2021-10-06 2023-04-18 株式会社明治 バクテロイデス属細菌の増殖促進剤
CN114224925A (zh) * 2021-12-23 2022-03-25 广东格物生物科技有限公司 一种调节肠道健康的益生菌组合物及其制备方法
CN115025116B (zh) * 2022-07-13 2023-11-21 纽湃腾（北京）医药科技有限公司 一种显著改善胃食管反流伴肠易激综合征的组合物及其应用
WO2025106584A1 (en) * 2023-11-14 2025-05-22 Kate Farms, Inc. Infant formula

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020044957A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition
US20030040492A1 (en) * 2000-03-01 2003-02-27 Ferdinand Haschke Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US7141554B2 (en) 2000-07-24 2006-11-28 Nestec S.A. Method of treating irritable bowel syndrome
EP1917969A1 (en) * 2006-10-23 2008-05-07 Velleja Research SRL Compositions for preventing depletion of the intestinal flora and organ damage following antibiotic treatment
EP2014181A2 (en) * 2007-06-15 2009-01-14 S.I.I.T. S.r.l. Servizio Internazionale Imballaggi Termosaldanti Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/or alterations of the normal intestinal flora

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
ES2123903T5 (es) 1995-08-04 2011-02-22 N.V. Nutricia Composición nutritiva conteniendo fibra.
ATE308254T1 (de) * 1998-12-15 2005-11-15 Nestle Sa Ballaststoffemischung für enterale zusammensetzung
EP1243273A1 (en) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
GB0308104D0 (en) 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
ITMI20040956A1 (it) 2004-05-12 2004-08-12 Curti Alessandro Composizioni alimentari
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
ATE451845T1 (de) * 2005-10-05 2010-01-15 Nestec Sa Verwendung einer nährstoffformulierung zur förderung des aufholwachstums
CA2668613C (en) 2006-11-07 2016-12-13 The Procter & Gamble Company Fiber containing compositions and methods of making and using same
US8263164B2 (en) 2007-07-18 2012-09-11 Campina Nederland Holding B.V. Heat stable nutritional beverage and method of preparing it
WO2009075564A1 (en) 2007-12-10 2009-06-18 N.V. Nutricia Paediatric fibre mixture
JP5992654B2 (ja) 2007-12-21 2016-09-14 ニュートリー株式会社 整腸及び／又は便通改善のための組成物
BR112012011294B1 (pt) * 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040492A1 (en) * 2000-03-01 2003-02-27 Ferdinand Haschke Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
US7141554B2 (en) 2000-07-24 2006-11-28 Nestec S.A. Method of treating irritable bowel syndrome
US20020044957A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
EP1917969A1 (en) * 2006-10-23 2008-05-07 Velleja Research SRL Compositions for preventing depletion of the intestinal flora and organ damage following antibiotic treatment
EP2014181A2 (en) * 2007-06-15 2009-01-14 S.I.I.T. S.r.l. Servizio Internazionale Imballaggi Termosaldanti Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/or alterations of the normal intestinal flora

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BABB, RR: "Intestinal Gas (Medical Information)", WEST J. MED., vol. 127, 1977, pages 362 - 363
BLISS ET AL.: "Supplementation with Gum Arabic Fiber Increases Fecal Ntrogen Excretion and Lowers Serum Urea Nitrogen Concentrationin Chronic Renal Failure Patients Consuming a Low-protein Diet", AM. J. CLIN. NUTR., vol. 63, no. 3, 1996, pages 392 - 398
CHERBUT ET AL.: "Acacia Gum is a Bifidogenic Dietary Fibre with High Digestive Tolerance in Healthy Humans", MICROBIAL ECOLOGY IN HEALTH AND DISEASE, vol. 15, no. 1, 2003, pages 43 - 50, XP009085042
ESPEN, GUIDELINES, 2006
GLENN R. GIBSON; MARCEL B. ROBERFROID: "Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics", J. NUTR., vol. 125, 1995, pages 1401 - 1412, XP002153893
MACFARLANE GT, STEED H, MACFARLANE S: "Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics", J. APPL. MICROBIOL., vol. 104, 2008, pages 305 - 344, XP002623021, DOI: 10.1111/j.1365-2672.2007.03520.x *
MARTIN GR ET AL.: "Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome", AM. J. PHYSIOL., GASTROINTEST., LIVER PHYSIOL., 2005, pages G431 - G438
MOLLY ET AL.: "Development of a 5-step multichamber reactor as a simulation of the human intestinal microbial ecosystem", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 39, 1993, pages 254 - 258, XP035173191, DOI: doi:10.1007/BF00228615
MURTAGH FEM; ADDINGTON-HALL J; HIGGINSON IJ.: "The Prevalence of Symptoms in End-Stage Renal Disease: A Systematic Review", ADVANCES IN CHRONIC KIDNEY DISEASE, vol. 14, no. 1, 2007, pages 82 - 89
PARISI G; ZILLI M; MIANI M ET AL.: "High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG)", DIG DIS SCI, vol. 47, no. 8, 2002, pages 1697 - 704, XP002527707, DOI: doi:10.1023/A:1016419906546
PATRICK P; GOHMAN S; MARX S; DELEGGE M; GREENBERG N.: "Effect of Supplements of Partially Hydrolyzed Guar Gum on the Occurrence of Constipation and Use of Laxative Agents", JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, vol. 98, no. 8, 1998, pages 912 - 914
PATTI EISENBERG: "An Overview of Diarrhea in the Patient Receiving Enteral Nutrition", GASTROENTEROLOGY NURSING, vol. 25, no. 3, 2002, pages 95 - 104
POSSEMIERS ET AL.: "PCR-DGGE-based quantification of stability of the microbial community in a simulator of the human intestinal microbial ecosystem", FAMS MICROBIOLOGY ECOLOGY, vol. 49, 2004, pages 495 - 507
ROCHAT ET AL., METHOD OF TREATING IRRITABLE BOWEL SYNDROME
ROSS ET AL.: "A Study of the Effects of Dietary Gum Arabic in Humans", AM. J. CLIN. NUTR., vol. 37, no. 3, 1983, pages 368 - 375, XP002411808
SALMINEN S; OUWEHAND A.; BENNO Y. ET AL.: "Probiotics: how should they be defined?", TRENDS FOOD SCI. TECHNOL., vol. 10, 1999, pages 107 - 10, XP055150446
SLAVIN JL; GREENBERG NA.: "Partially Hydrolyzed Guar Gum: Clinical Nutrition Uses", NUTRITION, vol. 19, 2003, pages 549 - 552
SORIANO CV; HIBLER KD; MAXEY KI.: "Long-term fiber intervention program: reduction in enema use at a developmental care facility", JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, vol. 100, no. 9, 2005, pages A82
TAKAHASHI H; YANG S; HAYASKI C; KIM M; YAMANAKA J; YAMAMOTO T.: "Influence of partially hydrolyzed guar gum on constipation in women", JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 40, 1994, pages 251 - 259
VAN DEN ABBEELE ET AL.: "In vitro model to study the modulation of the mucin-adhered bacterial community", APPL. MICROBIOL. BIOTECHNOL., 2009
VELAZQUEZ M; DAVIES C; MARETT R; SLAVIN J; FEIRTAG J.: "Effect of oligosaccharides and fibre substitutes on short chain fatty acid production by human faeca microflora", ANAEROBE, vol. 6, no. 2, 2000, pages 87 - 92
WAPNIR ET AL.: "Gum Arabic Promotes Rat Jejunal Sodium and Water Absorption from Oral Rehydration Solutions in Two Models of Diarrhea", GASTROENTEROLOGY, vol. 112, no. 6, 1997, pages 1979 - 1985
ZHAO Y: "Thl and Th2 cytokines in organ transplantation: paradigm lost", CRIT REV IMMUNOL., vol. 19, no. 2, 1999, pages 155 - 72

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11771102B2 (en) 2011-06-20 2023-10-03 H.J. Heinz Company Brands Llc Probiotic compositions and methods
US11109603B2 (en) 2011-06-20 2021-09-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
WO2012175639A1 (en) * 2011-06-22 2012-12-27 Universite De Rouen Arabinogalactan proteins for use as an antiparasitic agent
US10087480B2 (en) 2011-10-12 2018-10-02 Gut Guide Oy Raising and diagnosing of serotonin level
WO2013054001A1 (en) * 2011-10-12 2013-04-18 Gut Guide Oy Raising and diagnosing of serotonin level
US9662358B2 (en) 2011-10-18 2017-05-30 Nestec S.A. Composition for use in the promotion of healthy bone growth and/or in the treatment of bone disease
EP2768312B1 (en) 2011-10-18 2015-12-09 Nestec S.A. Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
WO2013067147A1 (en) * 2011-11-01 2013-05-10 Jimmy Lu A composition and method of delivery of l-arabinose and select compounds
WO2013132456A1 (en) 2012-03-07 2013-09-12 Aboca Societa' S.P.A. Societa' Agricola Prebiotic mixture
ITRM20120084A1 (it) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola Miscela prebiotica.
US9907827B2 (en) 2012-03-07 2018-03-06 Aboca S.P.A. Societá Agricola Prebiotic mixture
WO2014007636A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
WO2014007635A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Dietary fibre for use in the treatment of a gastro-intestinal side-effect of a nutrition or medicament
WO2014007606A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
JP2015535280A (ja) * 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン 胃腸管において有益な細菌を刺激する方法及び組成物
JP2018111711A (ja) * 2012-11-01 2018-07-19 レイクスユニフェルシテイト フローニンゲン リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩
US11458174B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458173B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US12083151B2 (en) 2012-11-23 2024-09-10 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11389490B2 (en) 2012-11-23 2022-07-19 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 (en) 2012-11-23 2022-10-11 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102301577B1 (ko) 2012-11-27 2021-09-13 상하이 지아오통 유니버시티 장 미생물무리 균형을 위한 조성물 및 이의 제조 및 용도
JP2016505533A (ja) * 2012-11-27 2016-02-25 シャンハイ ジャオ トン ユニバーシティ 腸内微生物叢の平衡を保つための組成物、該組成物の製法、および、該組成物の利用
KR20150088263A (ko) * 2012-11-27 2015-07-31 상하이 지아오통 유니버시티 장 미생물무리 균형을 위한 조성물 및 이의 제조 및 용도
JP2016509002A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
US10967011B2 (en) 2013-02-04 2021-04-06 Seres Therapeutics, Inc. Compositions and methods
JP2019104742A (ja) * 2013-02-04 2019-06-27 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
US11730775B2 (en) 2013-02-04 2023-08-22 Seres Therapeutics, Inc. Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US10064901B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Compositions and methods
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US11666612B2 (en) 2013-03-15 2023-06-06 Seres Therapeutics, Inc Network-based microbial compositions and methods
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10881696B2 (en) 2013-03-15 2021-01-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
JP2016516743A (ja) * 2013-03-28 2016-06-09 クラサド インコーポレイテッド 精神神経疾患または老化における認知機能障害および情緒障害の予防または治療に使用するためのガラクトオリゴ糖組成物
US12409197B2 (en) 2013-11-25 2025-09-09 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11266699B2 (en) 2013-11-25 2022-03-08 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11918612B2 (en) 2013-11-25 2024-03-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016019597A1 (zh) * 2014-08-07 2016-02-11 逯明福 综合营养粉及其制备方法
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
CN108245530A (zh) * 2016-12-28 2018-07-06 兰州奇正生态健康品有限公司 一种具有润肠通便作用的组合物及其制备方法与用途
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
EP3466276A1 (en) 2017-10-05 2019-04-10 Pharmactive Biotech Products, S.L. Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
WO2019068466A1 (en) 2017-10-05 2019-04-11 Pharmactive Biotech Products, S.L. FOOD FIBER COMPOSITION FOR THE PROTECTION OF BIOACTIVE COMPOUNDS DURING THE PHYSIOLOGICAL DIGESTION PROCESS
US12214002B2 (en) 2017-10-30 2025-02-04 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
EP3866615B1 (en) 2018-10-15 2023-08-30 Freedom Health, LLC Dietary supplement for treating dysbiosis
AU2019410086B2 (en) * 2018-12-19 2025-04-17 Cosucra Groupe Warcoing S.A. Composition comprising chicory root and pea cell wall fiber for treating Brachyspira infections
US12290545B2 (en) 2018-12-19 2025-05-06 Cosucra Groupe Warcoing S.A. Composition comprising chicory root and pea cell wall fiber for treating Brachyspira infections
WO2020127630A1 (en) * 2018-12-19 2020-06-25 Cosucra Groupe Warcoing S.A. Composition comprising chicory root and pea cell wall fiber for treating brachyspira infections
US11622974B2 (en) 2019-01-18 2023-04-11 C.P. Kelco U.S., Inc. Prebiotic composition and its use
WO2020150389A3 (en) * 2019-01-18 2020-11-05 Cp Kelco U.S., Inc. Prebiotic composition and its use
WO2020161522A1 (en) * 2019-02-06 2020-08-13 Thd S.P.A. Fiber-based composition
FR3093427A1 (fr) * 2019-03-05 2020-09-11 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
WO2020178391A1 (fr) * 2019-03-05 2020-09-10 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
WO2020239996A1 (en) 2019-05-29 2020-12-03 N.V. Nutricia Non-digestible oligosaccharides for decreased colonic protein fermentation
WO2022122958A1 (en) 2020-12-09 2022-06-16 N.V. Nutricia Fibre mixture for young children
EP4119135A1 (fr) * 2021-07-13 2023-01-18 Luxia Scientific Methodes pour reequilibrer la flore intestinale chez les patients souffrant de la maladie de parkinson
WO2023209258A1 (es) * 2022-04-26 2023-11-02 Servicio Andaluz De Salud Composición para la rehabilitación intestinal
ES2955633A1 (es) * 2022-04-26 2023-12-04 Servicio Andaluz De Salud Composición para la rehabilitación intestinal
GR1011003B (el) * 2024-02-28 2025-07-22 Cloudpharm Private Company, Συμπληρωμα διατροφης για την αντιμετωπιση της απωλειας της οστικης πυκνοτητας (οστεοπενια)
RU2828960C1 (ru) * 2024-05-16 2024-10-21 Общество С Ограниченной Ответственностью "Нутризет" Способ лечения питательной недостаточности у больных с сепсисом энтеральной смесью, содержащей метабиотический комплекс и β-глюканы

Also Published As

Publication number Publication date
EP2498626B1 (en) 2015-06-17
DK2498626T3 (en) 2015-07-13
AU2010319490A1 (en) 2012-05-03
JP2016166176A (ja) 2016-09-15
BR112012011294A2 (pt) 2015-09-15
MX2012004778A (es) 2012-06-01
US9192179B2 (en) 2015-11-24
CN104206946A (zh) 2014-12-17
CA2777941A1 (en) 2011-05-19
US10015978B2 (en) 2018-07-10
CN102595934A (zh) 2012-07-18
AU2010319490B2 (en) 2015-03-19
PH12012500687A1 (en) 2012-10-29
CA2777941C (en) 2018-08-14
HK1172516A1 (en) 2013-04-26
BR112012011294B1 (pt) 2018-03-20
JP6006117B2 (ja) 2016-10-12
EP2498626A1 (en) 2012-09-19
US20160100617A1 (en) 2016-04-14
IN2012DN03632A (enExample) 2015-06-26
JP2013510865A (ja) 2013-03-28
US20120269865A1 (en) 2012-10-25
JP6205003B2 (ja) 2017-09-27
MX336032B (es) 2016-01-07
RU2012123959A (ru) 2013-12-20
ES2545597T3 (es) 2015-09-14

Similar Documents

Publication Publication Date Title
US10015978B2 (en) Nutritional composition for promoting gut microbiota balance and health
US12290492B2 (en) Extensional viscosity to promote safe swallowing of food boluses
CN102573517B (zh) 稳定的增稠剂制品
CN105828641A (zh) 用于减少肠病原体的营养组合物
US20160192686A1 (en) Cohesive liquid bolus comprising molecules providing visco-elasticity
JP2015527076A (ja) 増粘された乳製品又は乳製品様製品及びそれらを製造するための方法
HK1172516B (en) Nutritional composition for promoting gut microbiota balance and health

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080049822.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10779417

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012538966

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12012500687

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010319490

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010779417

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2777941

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/004778

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 3632/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010319490

Country of ref document: AU

Date of ref document: 20101111

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1201002172

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13502918

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012123959

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012011294

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012011294

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120511